Overview

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

Status:
Enrolling by invitation

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate long-term safety in participants with metastasis solid tumors that are benefitting from continuation with sacituzumab govitecan-hziy.

Phase:

Phase 4

Details

Lead Sponsor:

Gilead Sciences
Immunomedics, Inc.

Treatments:

Camptothecin
Immunoconjugates